BIOMARIN PHARMACEUTICAL INC Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax of -$2.06 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax · last filed 2015-11-02
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, before tax for the quarter ending 2015-09-30 was -$2.06M, a 119.95% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, before tax for the quarter ending 2015-06-30 was -$7.87M, a 487.64% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, before tax for the quarter ending 2015-03-31 was $9.04M, a 597.30% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, before tax for the quarter ending 2014-12-31 was $4.63M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2014 was $18.28M.
- BIOMARIN PHARMACEUTICAL INC other comprehensive income (loss), derivatives qualifying as hedges, before tax for fiscal 2013 was -$2.23M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax 12 month |
|---|---|---|---|---|
| 2015-09-30 | -$2.06M 10-Q · filed 2015-11-02 | -$9.93M derived: sum of 2 quarters · filed 2015-11-02 | -$893.00K 10-Q · filed 2015-11-02 | $3.73M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-06-30 | -$7.87M 10-Q · filed 2015-08-05 | $1.17M 10-Q · filed 2015-08-05 | $5.80M derived: sum of 3 quarters · filed 2015-08-05 | $16.13M derived: sum of 4 quarters · filed 2015-11-02 |
| 2015-03-31 | $9.04M 10-Q · filed 2015-05-05 | $13.66M derived: sum of 2 quarters · filed 2015-05-05 | $24.00M derived: sum of 3 quarters · filed 2015-11-02 | $26.02M derived: sum of 4 quarters · filed 2015-11-02 |
| 2014-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $14.96M derived: sum of 2 quarters · filed 2015-11-02 | $16.99M derived: sum of 3 quarters · filed 2015-11-02 | $18.28M 10-K · filed 2015-03-02 |
| 2014-09-30 | $10.33M 10-Q · filed 2015-11-02 | $12.36M derived: sum of 2 quarters · filed 2015-11-02 | $13.66M 10-Q · filed 2015-11-02 | $13.34M derived: sum of 4 quarters · filed 2015-11-02 |
| 2014-06-30 | $2.03M 10-Q · filed 2015-08-05 | $3.33M 10-Q · filed 2015-08-05 | $3.01M derived: sum of 3 quarters · filed 2015-08-05 | -$165.00K derived: sum of 4 quarters · filed 2015-08-05 |
| 2014-03-31 | $1.30M 10-Q · filed 2015-05-05 | $982.00K derived: sum of 2 quarters · filed 2015-05-05 | -$2.19M derived: sum of 3 quarters · filed 2015-05-05 | -$2.50M derived: sum of 4 quarters · filed 2015-05-05 |
| 2013-12-31 | -$314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$3.49M derived: sum of 2 quarters · filed 2015-03-02 | -$3.79M derived: sum of 3 quarters · filed 2015-03-02 | -$2.23M 10-K · filed 2015-03-02 |
| 2013-09-30 | -$3.18M 10-Q · filed 2014-10-28 | -$3.48M derived: sum of 2 quarters · filed 2014-10-28 | -$1.92M 10-Q · filed 2014-10-28 | |
| 2013-06-30 | -$302.00K 10-Q · filed 2014-07-31 | $1.26M 10-Q · filed 2014-07-31 | ||
| 2013-03-31 | $1.56M 10-Q · filed 2014-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |